ProCE Banner Activity

An Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies


Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 experts in managing patients with hematologic malignancies.

Released: December 06, 2021

Expiration: December 05, 2022

No longer available for credit.
Begin Activity



Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor of Medicine
Director, CLL Program
Columbia University Medical Center
New York, New York

John P. Leonard

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from


BeiGene Ltd

Additional Information

Program Medium

This program has been made available online.